Literature DB >> 23616677

Venous thromboembolism due to suspected interaction between rivaroxaban and nevirapine.

Duane Bates1, Bruce Dalton, Janet Gilmour, Jeff Kapler.   

Abstract

Entities:  

Year:  2013        PMID： 23616677      PMCID： PMC3633497          DOI： 10.4212/cjhp.v66i2.1235

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  17 in total

1.  Phenytoin-induced reduction in sirolimus levels.

Authors:  Duane Bates; Kelly W Burak; Carla S Coffin; Tammy Ying; Echo-Marie Enns
Journal:  Can J Hosp Pharm       Date:  2011-07

2.  Proposal for a new tool to evaluate drug interaction cases.

Authors:  John R Horn; Philip D Hansten; Lingtak-Neander Chan
Journal:  Ann Pharmacother       Date:  2007-03-27       Impact factor: 3.154

3.  Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories.

Authors:  L M Asmis; L Alberio; A Angelillo-Scherrer; W Korte; A Mendez; G Reber; B Seifert; H Stricker; D A Tsakiris; W A Wuillemin
Journal:  Thromb Res       Date:  2011-08-15       Impact factor: 3.944

4.  Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

Authors:  Melanie A Thompson; Judith A Aberg; Jennifer F Hoy; Amalio Telenti; Constance Benson; Pedro Cahn; Joseph J Eron; Huldrych F Günthard; Scott M Hammer; Peter Reiss; Douglas D Richman; Giuliano Rizzardini; David L Thomas; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2012-07-25       Impact factor: 56.272

Review 5.  Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery.

Authors:  Stephanie N Melillo; James V Scanlon; Benjamin P Exter; Michael Steinberg; Courtney I Jarvis
Journal:  Ann Pharmacother       Date:  2010-04-27       Impact factor: 3.154

6.  BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.

Authors:  A G G Turpie; W D Fisher; K A Bauer; L M Kwong; M W Irwin; P Kälebo; F Misselwitz; M Gent
Journal:  J Thromb Haemost       Date:  2005-11       Impact factor: 5.824

Review 7.  Risk factors for venous thromboembolism in patients with human immunodeficiency virus infection.

Authors:  Katie L Kiser; Melissa E Badowski
Journal:  Pharmacotherapy       Date:  2010-12       Impact factor: 4.705

8.  Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.

Authors:  Wolfgang Mueck; Anthonie W A Lensing; Giancarlo Agnelli; Hervé Decousus; Paolo Prandoni; Frank Misselwitz
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

Review 9.  Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.

Authors:  Jonathan Douxfils; François Mullier; Claire Loosen; Christian Chatelain; Bernard Chatelain; Jean-Michel Dogné
Journal:  Thromb Res       Date:  2012-09-21       Impact factor: 3.944

Review 10.  Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Authors:  Celeste B Burness; Kate McKeage
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546
View more
  5 in total

1.  Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy.

Authors:  Daniele Pastori; Ivano Mezzaroma; Pasquale Pignatelli; Francesco Violi; Gregory Y H Lip
Journal:  Br J Clin Pharmacol       Date:  2019-01-11       Impact factor: 4.335

Review 2.  Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions.

Authors:  Sara R Vazquez
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review.

Authors:  Allen Li; Ming K Li; Mark Crowther; Sara R Vazquez
Journal:  Thromb Res       Date:  2020-08-11       Impact factor: 3.944

Review 4.  Stroke and Systemic Thromboembolism Prevention in People Living With Human Immunodeficiency Virus With Atrial Fibrillation: A Review of Its Implications for Clinical Practice.

Authors:  Pilar Vizcarra; Silvia Guillemi; Oghenowede Eyawo; Robert S Hogg; Julio S Montaner; Matthew Bennett
Journal:  CJC Open       Date:  2019-07-02

Review 5.  Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase.

Authors:  Silvia Fernandez; Camille Lenoir; Caroline Flora Samer; Victoria Rollason
Journal:  J Pers Med       Date:  2021-03-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.